The business of developing antibacterials
Although some dazzling technical approaches have fallen short, dozens of small companies and a few major pharmas seek new products for this medically crucial, modest-growth market.
Gespeichert in:
| Veröffentlicht in: | Nature biotechnology 2006-12, Vol.24 (12), p.1521-1528 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1528 |
|---|---|
| container_issue | 12 |
| container_start_page | 1521 |
| container_title | Nature biotechnology |
| container_volume | 24 |
| creator | Fox, Jeffrey L |
| description | Although some dazzling technical approaches have fallen short, dozens of small companies and a few major pharmas seek new products for this medically crucial, modest-growth market. |
| doi_str_mv | 10.1038/nbt1206-1521 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_68241166</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A191176303</galeid><sourcerecordid>A191176303</sourcerecordid><originalsourceid>FETCH-LOGICAL-c625t-d7db4ce3ea3684cab90dd245987eb7766557c7dddf0eb005719a0f4fa56ced3a3</originalsourceid><addsrcrecordid>eNqNkt9rFDEQx4MotlbffJZDUCi4NbObTHYfS_FHoVDQ6mvIJrNnyl72THal_e_NcYvXCqWXPMyQfOabIfNl7DXwE-BV_TG0I5QcC5AlPGGHIEXOscGnOee1KjhIPGAvUrrmnKNAfM4OQAFyLvGQHV_9okU7JR8opcXQLRz9oX5Y-7BcmDD61tiRojd9esmedTnQqzkesR-fP12dfS0uLr-cn51eFBZLORZOuVZYqshUWAtr2oY7VwrZ1IpapRClVFY55zpObe5BQWN4Jzoj0ZKrTHXE3m9113H4PVEa9conS31vAg1T0liXAgAxg2__A6-HKYbcmy43qwYoM3SyhZamJ-1DN4zR2LwdrbwdAnU-n59iCTXm5sS-BdAAKKx4lQuO7xVkZqSbcWmmlPT592_3xR9j99W9_Lm_7oa9q_thy9o4pBSp0-voVybeauB64yg9O0pvHJXxN_MvT-2K3A6eLZSBdzNgkjV9F02wPu24WnDRVDJzxZZL-SosKe7G9cDD83iDGadI_wTv-r36C3GU54k</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>222228112</pqid></control><display><type>article</type><title>The business of developing antibacterials</title><source>MEDLINE</source><source>Nature</source><source>Alma/SFX Local Collection</source><creator>Fox, Jeffrey L</creator><creatorcontrib>Fox, Jeffrey L</creatorcontrib><description>Although some dazzling technical approaches have fallen short, dozens of small companies and a few major pharmas seek new products for this medically crucial, modest-growth market.</description><identifier>ISSN: 1087-0156</identifier><identifier>EISSN: 1546-1696</identifier><identifier>DOI: 10.1038/nbt1206-1521</identifier><identifier>PMID: 17160056</identifier><identifier>CODEN: NABIF9</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Agriculture ; Anti-Bacterial Agents - biosynthesis ; Anti-Bacterial Agents - immunology ; Antibacterial agents ; Antibiotics ; Antibody Specificity - immunology ; Backup software ; Bacterial Infections - immunology ; Bacterial Infections - prevention & control ; Bioinformatics ; Biological and medical sciences ; Biomedical Engineering/Biotechnology ; Biomedicine ; Biotechnology ; Clinical Trials as Topic ; Commerce ; Daptomycin ; Drug Design ; Drug Industry - economics ; Drug Industry - trends ; Drug Resistance, Microbial ; feature ; Financing, Government ; Fundamental and applied biological sciences. Psychology ; Immunoglobulins, Intravenous - biosynthesis ; Immunoglobulins, Intravenous - therapeutic use ; Industrywide conditions ; Investments ; Legislation. General informations ; Life Sciences ; Methicillin Resistance - drug effects ; Methicillin Resistance - immunology ; Pharmaceutical industry ; Product development ; R&D ; Research & development ; Research Support as Topic ; Rifamycins ; Staphylococcus aureus - drug effects ; Staphylococcus aureus - immunology ; Startups ; Tetracyclines</subject><ispartof>Nature biotechnology, 2006-12, Vol.24 (12), p.1521-1528</ispartof><rights>Springer Nature Limited 2006</rights><rights>2007 INIST-CNRS</rights><rights>COPYRIGHT 2006 Nature Publishing Group</rights><rights>Copyright Nature Publishing Group Dec 2006</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c625t-d7db4ce3ea3684cab90dd245987eb7766557c7dddf0eb005719a0f4fa56ced3a3</citedby><cites>FETCH-LOGICAL-c625t-d7db4ce3ea3684cab90dd245987eb7766557c7dddf0eb005719a0f4fa56ced3a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2727,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18404935$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17160056$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Fox, Jeffrey L</creatorcontrib><title>The business of developing antibacterials</title><title>Nature biotechnology</title><addtitle>Nat Biotechnol</addtitle><addtitle>Nat Biotechnol</addtitle><description>Although some dazzling technical approaches have fallen short, dozens of small companies and a few major pharmas seek new products for this medically crucial, modest-growth market.</description><subject>Agriculture</subject><subject>Anti-Bacterial Agents - biosynthesis</subject><subject>Anti-Bacterial Agents - immunology</subject><subject>Antibacterial agents</subject><subject>Antibiotics</subject><subject>Antibody Specificity - immunology</subject><subject>Backup software</subject><subject>Bacterial Infections - immunology</subject><subject>Bacterial Infections - prevention & control</subject><subject>Bioinformatics</subject><subject>Biological and medical sciences</subject><subject>Biomedical Engineering/Biotechnology</subject><subject>Biomedicine</subject><subject>Biotechnology</subject><subject>Clinical Trials as Topic</subject><subject>Commerce</subject><subject>Daptomycin</subject><subject>Drug Design</subject><subject>Drug Industry - economics</subject><subject>Drug Industry - trends</subject><subject>Drug Resistance, Microbial</subject><subject>feature</subject><subject>Financing, Government</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Immunoglobulins, Intravenous - biosynthesis</subject><subject>Immunoglobulins, Intravenous - therapeutic use</subject><subject>Industrywide conditions</subject><subject>Investments</subject><subject>Legislation. General informations</subject><subject>Life Sciences</subject><subject>Methicillin Resistance - drug effects</subject><subject>Methicillin Resistance - immunology</subject><subject>Pharmaceutical industry</subject><subject>Product development</subject><subject>R&D</subject><subject>Research & development</subject><subject>Research Support as Topic</subject><subject>Rifamycins</subject><subject>Staphylococcus aureus - drug effects</subject><subject>Staphylococcus aureus - immunology</subject><subject>Startups</subject><subject>Tetracyclines</subject><issn>1087-0156</issn><issn>1546-1696</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNkt9rFDEQx4MotlbffJZDUCi4NbObTHYfS_FHoVDQ6mvIJrNnyl72THal_e_NcYvXCqWXPMyQfOabIfNl7DXwE-BV_TG0I5QcC5AlPGGHIEXOscGnOee1KjhIPGAvUrrmnKNAfM4OQAFyLvGQHV_9okU7JR8opcXQLRz9oX5Y-7BcmDD61tiRojd9esmedTnQqzkesR-fP12dfS0uLr-cn51eFBZLORZOuVZYqshUWAtr2oY7VwrZ1IpapRClVFY55zpObe5BQWN4Jzoj0ZKrTHXE3m9113H4PVEa9conS31vAg1T0liXAgAxg2__A6-HKYbcmy43qwYoM3SyhZamJ-1DN4zR2LwdrbwdAnU-n59iCTXm5sS-BdAAKKx4lQuO7xVkZqSbcWmmlPT592_3xR9j99W9_Lm_7oa9q_thy9o4pBSp0-voVybeauB64yg9O0pvHJXxN_MvT-2K3A6eLZSBdzNgkjV9F02wPu24WnDRVDJzxZZL-SosKe7G9cDD83iDGadI_wTv-r36C3GU54k</recordid><startdate>20061201</startdate><enddate>20061201</enddate><creator>Fox, Jeffrey L</creator><general>Nature Publishing Group UK</general><general>Nature</general><general>Nature Publishing Group</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QO</scope><scope>7QP</scope><scope>7QR</scope><scope>7T7</scope><scope>7TK</scope><scope>7TM</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>M7S</scope><scope>MBDVC</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>Q9U</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20061201</creationdate><title>The business of developing antibacterials</title><author>Fox, Jeffrey L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c625t-d7db4ce3ea3684cab90dd245987eb7766557c7dddf0eb005719a0f4fa56ced3a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Agriculture</topic><topic>Anti-Bacterial Agents - biosynthesis</topic><topic>Anti-Bacterial Agents - immunology</topic><topic>Antibacterial agents</topic><topic>Antibiotics</topic><topic>Antibody Specificity - immunology</topic><topic>Backup software</topic><topic>Bacterial Infections - immunology</topic><topic>Bacterial Infections - prevention & control</topic><topic>Bioinformatics</topic><topic>Biological and medical sciences</topic><topic>Biomedical Engineering/Biotechnology</topic><topic>Biomedicine</topic><topic>Biotechnology</topic><topic>Clinical Trials as Topic</topic><topic>Commerce</topic><topic>Daptomycin</topic><topic>Drug Design</topic><topic>Drug Industry - economics</topic><topic>Drug Industry - trends</topic><topic>Drug Resistance, Microbial</topic><topic>feature</topic><topic>Financing, Government</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Immunoglobulins, Intravenous - biosynthesis</topic><topic>Immunoglobulins, Intravenous - therapeutic use</topic><topic>Industrywide conditions</topic><topic>Investments</topic><topic>Legislation. General informations</topic><topic>Life Sciences</topic><topic>Methicillin Resistance - drug effects</topic><topic>Methicillin Resistance - immunology</topic><topic>Pharmaceutical industry</topic><topic>Product development</topic><topic>R&D</topic><topic>Research & development</topic><topic>Research Support as Topic</topic><topic>Rifamycins</topic><topic>Staphylococcus aureus - drug effects</topic><topic>Staphylococcus aureus - immunology</topic><topic>Startups</topic><topic>Tetracyclines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fox, Jeffrey L</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Nature biotechnology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fox, Jeffrey L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The business of developing antibacterials</atitle><jtitle>Nature biotechnology</jtitle><stitle>Nat Biotechnol</stitle><addtitle>Nat Biotechnol</addtitle><date>2006-12-01</date><risdate>2006</risdate><volume>24</volume><issue>12</issue><spage>1521</spage><epage>1528</epage><pages>1521-1528</pages><issn>1087-0156</issn><eissn>1546-1696</eissn><coden>NABIF9</coden><abstract>Although some dazzling technical approaches have fallen short, dozens of small companies and a few major pharmas seek new products for this medically crucial, modest-growth market.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>17160056</pmid><doi>10.1038/nbt1206-1521</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1087-0156 |
| ispartof | Nature biotechnology, 2006-12, Vol.24 (12), p.1521-1528 |
| issn | 1087-0156 1546-1696 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68241166 |
| source | MEDLINE; Nature; Alma/SFX Local Collection |
| subjects | Agriculture Anti-Bacterial Agents - biosynthesis Anti-Bacterial Agents - immunology Antibacterial agents Antibiotics Antibody Specificity - immunology Backup software Bacterial Infections - immunology Bacterial Infections - prevention & control Bioinformatics Biological and medical sciences Biomedical Engineering/Biotechnology Biomedicine Biotechnology Clinical Trials as Topic Commerce Daptomycin Drug Design Drug Industry - economics Drug Industry - trends Drug Resistance, Microbial feature Financing, Government Fundamental and applied biological sciences. Psychology Immunoglobulins, Intravenous - biosynthesis Immunoglobulins, Intravenous - therapeutic use Industrywide conditions Investments Legislation. General informations Life Sciences Methicillin Resistance - drug effects Methicillin Resistance - immunology Pharmaceutical industry Product development R&D Research & development Research Support as Topic Rifamycins Staphylococcus aureus - drug effects Staphylococcus aureus - immunology Startups Tetracyclines |
| title | The business of developing antibacterials |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T15%3A01%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20business%20of%20developing%20antibacterials&rft.jtitle=Nature%20biotechnology&rft.au=Fox,%20Jeffrey%20L&rft.date=2006-12-01&rft.volume=24&rft.issue=12&rft.spage=1521&rft.epage=1528&rft.pages=1521-1528&rft.issn=1087-0156&rft.eissn=1546-1696&rft.coden=NABIF9&rft_id=info:doi/10.1038/nbt1206-1521&rft_dat=%3Cgale_proqu%3EA191176303%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=222228112&rft_id=info:pmid/17160056&rft_galeid=A191176303&rfr_iscdi=true |